India, May 21 -- Invivyd, Inc. (IVVD), a biopharmaceutical company, Wednesday announced that during its CANOPY phase 3 trial Pemivibart conferred an 84 percent reduction in the risk of becoming sick from COVID-19, compared to placebo. The formal evaluation was for six months, with a follow up of further six months.
Pemgarda or pemivibart is a half-life extended investigational monoclonal antibody.
Meanwhile, FDA acknowledged that the benefit of repeat doses of COVID-19 vaccine boosters for Americans is uncertain.
Invivyd said it plans to engage FDA shortly on an expedited pathway to develop scalable COVID-19 prevention and treatment options.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
Invivyed, ...